Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, CanadaDr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.
Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.
Disclosures
Dr. Lin has consulted with the following companies on Continuing Medical Education programs:Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.
No clinical trials. No patents.
Recent Contributions to PracticeUpdate:
- Development of a Target Concentration Intervention to Individualize Paroxysmal Nocturnal Hemoglobinuria Treatment With Pegcetacoplan
- Real-World Experience of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria
- Predictors for Improvement in Patient-Reported Outcomes in Complement Inhibitor–Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Eculizumab and Ravulizumab
- Association of Glycaemic Index and Glycaemic Load With Risk of Type 2 Diabetes
- Association of Intake of SGLT2 Inhibitors With Functional Capacity and Quality of Life in Patients With Heart Failure
- Dosing Patterns of Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab in the US
- Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
- Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria: Use, Clinical Effectiveness, and Influence on HRQoL and Productivity
- Effects of Statin Therapy on Diagnoses of New-Onset Diabetes and Worsening Glycaemia
- Concomitant Use of Selective Serotonin Reuptake Inhibitors With OACs and Risk of Major Bleeding